作者: Amanda Leiter , John Doucette , Susan Krege , Chia-Chi Lin , Noah Hahn
DOI: 10.3233/BLC-160047
关键词: Cohort 、 Oncology 、 Body mass index 、 Metastatic Urothelial Carcinoma 、 Body surface area 、 Internal medicine 、 Surgery 、 Tolerability 、 Chemotherapy regimen 、 Combination therapy 、 Adverse effect 、 Medicine
摘要: Background: Obesity has been associated with worse outcomes in patients clinically localized urothelial cancer. However, this impact not evaluated metastatic disease. Objective: To assess the of obesity on cancer. Methods: Data from 537 were aggregated eight phase II and III clinical trials investigating first-line cisplatin-based combination therapy Chemotherapy regimen, adverse events, treatment response, survival compared across body mass index (BMI) surface area (BSA) categories. Results: BMI was classified according to WHO criteria ( 30 obese). BSA as either below or greater than equal (average for cohort (1.87 m2 males 1.66 m2 females). There no significant difference number chemotherapy cycles, response rate (overall progression-free) categories. events categories, but incidences embolic renal failure higher an average those a lower (6.6% vs. 3.1% p = 0.06; 5.9% 2.7% failure, p = 0.07). amongst categories. Conclusions: Obese cancer therapies have similar rates, outcomes, tolerability non-obese patients.